{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T04:06:48Z","timestamp":1767586008460,"version":"3.48.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.farma.2025.10.007","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:42:28Z","timestamp":1762209748000},"page":"T57-T63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["[Translated article] Influence of age on the efficacy of immunochemotherapy in non-small cell lung cancer"],"prefix":"10.1016","volume":"50","author":[{"given":"Alicia","family":"Aguado-Paredes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mo\u00f1ino-Dominguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Cordero-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Alegre-Del-Rey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.farma.2025.10.007_bb0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.farma.2025.10.007_bb0010","unstructured":"Surveillance, [accessed, 3, Jun]. https:\/\/seer.cancer.gov"},{"key":"10.1016\/j.farma.2025.10.007_bb0015","unstructured":"Cancer.org. [accessed, 4, Jun]. https:\/\/www.cancer.org\/es\/cancer\/tipos\/cancer-de-pulmon\/acerca\/que-es-cancer-de-pulmon.html"},{"issue":"4","key":"10.1016\/j.farma.2025.10.007_bb0020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.farma.2025.10.007_bb0025","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.farma.2025.10.007_bb0030","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/cells11030320","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects","volume":"11","author":"Tang","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.farma.2025.10.007_bb0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-020-00986-z","article-title":"Immunosenescence: a key player in cancer development","volume":"13","author":"Lian","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.farma.2025.10.007_bb0040","first-page":"218","article-title":"C\u00e1ncer de pulm\u00f3n en el paciente anciano","volume":"35","author":"Giron\u00e9s-Sarri\u00f3","year":"2021","journal-title":"Rev C\u00e1ncer"},{"issue":"1","key":"10.1016\/j.farma.2025.10.007_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/jcrt.jcrt_1523_23","article-title":"Immunosenescence and immunotherapy in older NSCLC patients","volume":"20","author":"Zhang","year":"2024","journal-title":"J Cancer Res Ther"},{"issue":"102394","key":"10.1016\/j.farma.2025.10.007_bb0050","article-title":"The use of immunotherapy in older patients with advanced non-small cell lung cancer","volume":"106","author":"Tagliamento","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.farma.2025.10.007_bb0055","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ctrv.2017.08.003","article-title":"Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter?","volume":"60","author":"Ferrara","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.farma.2025.10.007_bb0060","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41416-020-0986-4","article-title":"Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper","volume":"123","author":"Gomes","year":"2020","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.farma.2025.10.007_bb0065","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40266-021-00899-7","article-title":"Safety and effectiveness of immune checkpoint inhibitors in older patients with cancer: a systematic review of 48 real-world studies","volume":"38","author":"Luciani","year":"2021","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/j.farma.2025.10.007_bb0070","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jgo.2018.07.015","article-title":"The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population","volume":"10","author":"Sattar","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.farma.2025.10.007_bb0075","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejca.2019.08.027","article-title":"Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting","volume":"121","author":"Corbaux","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.farma.2025.10.007_bb0080","doi-asserted-by":"crossref","unstructured":"Aguado Paredes A, Mo\u00f1ino Dominguez L. Influence of age on the efficacy of immunochemotherapy in lung cancer. PROSPERO; 2025. CRD420251032819. [accessed 19 Abr 2025]. Available from: https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251032819","DOI":"10.1016\/j.farma.2025.10.007"},{"issue":"21","key":"10.1016\/j.farma.2025.10.007_bb0125","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.farma.2025.10.007_bb0085","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.farma.2025.10.007_bb0090","unstructured":"EPAR Keytruda. EMA. European Medicines Agency. [accessed 10 Jun 2024]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/keytruda."},{"issue":"7","key":"10.1016\/j.farma.2025.10.007_bb0095","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.farma.2025.10.007_bb0100","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.farma.2025.10.007_bb0105","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","article-title":"First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial","volume":"17","author":"Paz-Ares","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.farma.2025.10.007_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100273","article-title":"First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update","volume":"6","author":"Reck","year":"2021","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.farma.2025.10.007_bb0115","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non\u2013small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.farma.2025.10.007_bb0120","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jtho.2023.03.008","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-lung 3 part 2 trial","volume":"18","author":"Makharadze","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"13","key":"10.1016\/j.farma.2025.10.007_bb0130","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.7150\/jca.30723","article-title":"Aging, cancer and immunity","volume":"10","author":"Hong","year":"2019","journal-title":"J Cancer"},{"issue":"4","key":"10.1016\/j.farma.2025.10.007_bb0135","article-title":"Correlation between patients' age and cancer immunotherapy efficacy","volume":"8","author":"Wu","year":"2019","journal-title":"Oncoimmunology"},{"issue":"S13","key":"10.1016\/j.farma.2025.10.007_bb0140","doi-asserted-by":"crossref","first-page":"S1474","DOI":"10.21037\/jtd.2018.05.90","article-title":"Lung cancer, elderly and immune checkpoint inhibitors","volume":"10","author":"Casaluce","year":"2018","journal-title":"J Thorac Dis"},{"issue":"1","key":"10.1016\/j.farma.2025.10.007_bb0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/jcrt.jcrt_1523_23","article-title":"Immunosenescence and immunotherapy in older NSCLC patients","volume":"20","author":"Zhang","year":"2024","journal-title":"J Cancer Res Ther"},{"issue":"1","key":"10.1016\/j.farma.2025.10.007_bb0150","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/cancers16010145","article-title":"Immunotherapy in elderly patients\u2014single-center experience","volume":"16","author":"Ramos","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.farma.2025.10.007_bb0155","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.3390\/jcm12051833","article-title":"Immunotherapy in elderly patients affected by non-small cell lung cancer: a narrative review","volume":"12","author":"Montrone","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.farma.2025.10.007_bb0160","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3601942","article-title":"Relationship between patients' baseline characteristics and survival benefits in immunotherapy-treated non-small-cell lung cancer: a systematic review and meta-analysis","volume":"2022","author":"Hu","year":"2022","journal-title":"J Oncol"},{"issue":"5","key":"10.1016\/j.farma.2025.10.007_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100577","article-title":"The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression","volume":"7","author":"Kim","year":"2022","journal-title":"ESMO Open"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634325001424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634325001424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T02:25:06Z","timestamp":1767579906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634325001424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1130634325001424"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2025.10.007","relation":{},"ISSN":["1130-6343"],"issn-type":[{"type":"print","value":"1130-6343"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Influence of age on the efficacy of immunochemotherapy in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2025.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2025.06.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H).","name":"copyright","label":"Copyright"}]}}